<DOC>
	<DOCNO>NCT01328145</DOCNO>
	<brief_summary>The pathomechanisms COPD still fully understood , satisfy causal treatment inhibit progress disease . Available therapy case symptomatic . Experimental clinical observation suggest treatment ASA might beneficial treatment COPD term respiratory lung-functional improvement . To evaluate efficacy ASA add-on therapy COPD comparison placebo prospective , randomize , double-blind , placebo control study conduct . Adult male female patient ( n=74 ) proven COPD GOLD grade II-III randomize 2 group ( i.e . 37 patient per group , stratification accord smoke status gender ) . They receive either 500 mg ASA per day match placebo 12 week . Primary efficacy endpoint change lung-functional parameter FEV1 ( forced expiratory 1-second volume ) 12 week treatment . Secondary endpoint health score St. Georges respiratory questionnaire ( SGRQ ) Peak-flow ( PEF ) .</brief_summary>
	<brief_title>Acetylic Salicylic Acid Treatment Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<mesh_term>Salicylic Acid</mesh_term>
	<criteria>COPD GOLD II III Long term NSAIDS , pregnancy et al .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>